Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | SCARB1 | Q8WTV0 | 5/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12669919 | 0.88 | MAPK14 (0.55) | MAPK14KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL1599856 | 0.87 | MAPK14 (0.58) | MAPK14SCARB1 | |
| SCHEMBL1599556 | 0.85 | MAPK14 (0.70) | MAPK14KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL1899221 | 0.84 | MAPK14 (0.62) | MAPK14SCARB1 | |
| SCHEMBL1905020 | 0.83 | MAPK14 (0.67) | MAPK14KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL4418756 | 0.83 | MAPK14 (0.67) | MAPK14SCARB1 | |
| SCHEMBL4943425 | 0.83 | MAPK14 (0.82) | MAPK14SCARB1 | |
| SCHEMBL4412419 | 0.81 | MAPK14 (0.59) | MAPK14SCARB1 | |
| SCHEMBL1598835 | 0.81 | MAPK14 (0.80) | MAPK14SCARB1 | |
| SCHEMBL4420018 | 0.80 | MAPK14 (0.60) | MAPK14SCARB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006091862-A2 | CYTOKINE INHIBITORS AND THEIR USE IN THERAPY | KEMIA, INC. (US) | 2006-08-31 | — | — | WO | claimed |
| WO-2011063076-A1 | METHODS OF TREATING HEPATITIS C VIRUS WITH OXOACETAMIDE COMPOUNDS | ITHERX PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| US-20110117055-A1 | Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds | BRS - TUSTIN SAFEGUARD ASSOCIATES II, LLC | 2011-05-19 | — | — | US | disclosed |
| WO-2007058990-A2 | THERAPY USING CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2006091862-A2 | CYTOKINE INHIBITORS AND THEIR USE IN THERAPY | KEMIA, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117055-A1 | Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds | OAT, HAVCR2, OTC | MAPK14 3352/4885KDM4E 4464/4885ALDH1A1 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.